BENRALIZUMAB (Fasenra) prior authorization at Kaiser Permanente
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Kaiser Permanente requires Interleukin-5 Receptor alpha-directed Cytolytic Antibody prior-authorization documentation for BENRALIZUMAB (Fasenra): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Kaiser Permanente reviews BENRALIZUMAB (Fasenra) prior authorizations against its medical policy for Interleukin-5 Receptor alpha-directed Cytolytic Antibody. Kaiser Permanente-specific context: Integrated delivery system — care + insurance coordinated. California DMHC oversight is unique. CA IMR (Independent Medical Review) is a powerful external review track for Kaiser denials.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-5 Receptor alpha-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Kaiser Permanente's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Out-of-network non-emergency denials
- Specialty referrals delayed
- Mental health access (DMHC complaints common)
BENRALIZUMAB (Fasenra)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Eosinophil count threshold (≥300 cells/µL within 12 months)
- Step therapy requiring mepolizumab first within IL-5 class
- Indication restriction (severe asthma vs EGPA — December 2024)
Brand: Fasenra. IL-5 receptor α monoclonal antibody. Approved for severe eosinophilic asthma; expanded to eosinophilic granulomatosis with polyangiitis (EGPA) September 2024.
Manufacturer patient-assistance program: Benra360 Patient Support — relevant when a Kaiser Permanente denial sticks and the patient needs bridge access while appealing.
How Kaiser Permanente approaches Biologic drugs (mAbs and biosimilars) PAs
For BENRALIZUMAB (FASENRA), check whether the current Kaiser Permanente Biologic drugs (mAbs and biosimilars) policy cites specialty referrals delayed. Pharmacy-benefit review for BENRALIZUMAB (FASENRA) at Kaiser Permanente is routed through Kaiser Permanente Pharmacy (integrated in-house). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Kaiser Permanente; if denied, use the filing date and route printed on that denial notice. Kaiser Permanente's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Kaiser Permanente is domiciled in CA, so unresolved appeals escalate to the CA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://providers.kaiserpermanente.org) with the same packet plus an applicable, current clinical source supporting BENRALIZUMAB (Fasenra)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Kaiser Permanente denial on DenialHelp.
Contact Kaiser Permanente
- Provider portal: https://providers.kaiserpermanente.org
Frequently asked questions
What documentation does Kaiser Permanente need for BENRALIZUMAB (Fasenra) prior auth?
Kaiser Permanente's typical PA packet for BENRALIZUMAB (Fasenra): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-5 Receptor alpha-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Kaiser Permanente?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for BENRALIZUMAB (Fasenra) at Kaiser Permanente?
Preparation scenarios to check against the current notice and policy include: Out-of-network non-emergency denials; Specialty referrals delayed; Mental health access (DMHC complaints common). These are not measured frequency claims. For BENRALIZUMAB (Fasenra), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Kaiser Permanente typically require before approving BENRALIZUMAB (FASENRA)?
Kaiser Permanente's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For BENRALIZUMAB (FASENRA), attach the specific disease-activity instrument Kaiser Permanente accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Kaiser Permanente Pharmacy (integrated in-house). External-review escalation for Kaiser Permanente fully-insured policies sits with the CA insurance department.
How do I prep for a peer-to-peer with Kaiser Permanente on BENRALIZUMAB (Fasenra)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the BENRALIZUMAB (Fasenra) PA packet
Open ApprovalHelp — generate a BENRALIZUMAB (Fasenra) prior-auth packet tailored to Kaiser Permanente's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com